in the trunk mesoderm: BMP4 and FGF9. BMP4 is expressed in the lateral plate mesoderm and promotes lateral plate mesoderm development, whereas noggin (NOG)-mediated antagonism of BMP signaling is required for paraxial mesoderm and a low concentration of BMP4 induces the intermediate mesoderm 27 . FGF9 is specifically expressed in the intermediate mesoderm from the caudal through to the rostral trunk region 28 , and it effectively directs the differentiation of the hPSC-derived primitive streak into the intermediate mesoderm 9 . In our protocol, FGF9 is sufficient to specify the intermediate mesoderm; NOG is not needed (Fig. 1) .
Kidney organoid. The kidney functions as a 3D organ; hence, the culture conditions for differentiation need to switch from monolayer to 3D for the cells to form intact renal structures. Although continued 2D culture may be adequate to induce specific target cell types, as we have previously demonstrated 9 , the process of aggregation provides an increased cell density and volume within which cells are able to positionally reorganize with respect to each other. We chose day 7 of differentiation to transfer cells from a culture plate onto a Transwell filter as an aggregate grown at an air-media interface. Day 7 represents the stage of intermediate mesoderm that is considered to include not only progenitors of ureteric epithelium and metanephric mesenchyme but also progenitors of renal interstitium and endothelium 23 . This methodology of aggregation culture has been previously optimized for ex vivo culture of mouse embryonic kidneys 20 and reaggregations of mouse embryonic kidney cells 29 . A proper 3D environment allows this kidney progenitor mixture to undergo self-renogenesis to form a kidney organoid.
Alternative methods for generating kidney tissues
Several studies in which kidney progenitors were induced from hPSCs have been reported. Xia et al. 30 generated CK8-positive ureteric bud progenitor-like cells from hiPSCs and showed that those cells could integrate into ureteric epithelium in a reaggregate with mouse embryonic kidney cells. Other studies differentiated monolayer hPSCs into SIX2-positive metanephric mesenchyme that developed into renal tubules [31] [32] [33] . Taguchi et al. 34 carefully investigated the developmental process of the metanephric mesenchyme commitment in mice and used that knowledge to obtain metanephric mesenchyme cells from mouse ESCs and hiPSCs based on an embryoid body culture method. Their protocol focused on inducing the posterior intermediate mesoderm in order to obtain only the metanephric mesenchyme, without collecting duct, renal interstitial and endothelial cells. These induced metanephric mesenchyme cells could differentiate into not only renal tubules but also glomeruli by being combined with mouse dorsal spinal cord, a source of WNT signals that is known to induce nephrogenesis from the metanephric mesenchyme. Their follow-up study showed that these nephrons could become vascularized by incorporating host blood vessels when transplanted under a mouse renal capsule 35 . Morizane et al. 36 optimized the differentiation protocol using monolayer hPSCs to maximally induce the metanephric mesenchyme with 90% efficiency. Hence, similar to the above protocol, this did not induce collecting ducts or other nonepithelial renal cell types. The induced metanephric mesenchyme cells were also able to develop into nephron structures including renal tubules and glomeruli when stimulated by canonical WNT signaling using CHIR99021, a WNT agonist. Generated renal tubules revealed cell death in response to nephrotoxicants, cisplatin and gentamicin. Freedman et al. 37 used an approach in which they started the differentiation from hPSC-derived epiblast spheroids by sandwiching hPSCs between two layers of dilute Matrigel. Epiblast spheroids underwent epithelial-to-mesenchymal transition (EMT) to form a monolayer, followed by a mesenchymal-to-epithelial transition when reaggregated, resulting in the formation of renal tubules, glomeruli and endothelial cells.
Although all these studies exclusively induced either the ureteric epithelium or metanephric mesenchyme and their derivative cell types, our unique methodology generates both cell types at the same time 9 . In addition, our optimized protocol enables the generation of kidney organoids that contain not only the collecting duct and nephrons but also renal interstitium and an endothelial network 16 . Within the organoids, individual nephrons segment into distal tubules, early loops of Henle, proximal tubules and glomeruli containing podocytes that elaborate foot processes and can undergo vascularization. Such segmented nephrons are connected with collecting ducts and are surrounded by renal interstitium and an endothelial network. This protocol is clearly distinguished from others, as all anticipated cell types are simultaneously developed in the organoids.
Applications and limitations of the protocol
The differentiation of hPSCs using this protocol recapitulates the developmental process of human kidney organogenesis. Therefore, this protocol can be used as a platform for a variety of studies, such as understanding human development, modeling renal disease and nephrotoxic drug screening. For instance, we have used this protocol to investigate mediolateral and anteroposterior (AP) patterning during trunk mesoderm development 9, 16, 38 . In addition, as kidney organoids contain all components of the kidney, kidney organoids can be used for studying the development of each distinct cell type present within the human kidney. Kidney organoids can be also used to test renal tubular damage in response to nephrotoxic drugs. We have confirmed proximal tubule-specific cell death in kidney organoids after adding 5-20 µM cisplatin to the culture medium for 1 d 16 . This demonstrated the presence of proximal tubules, which are sufficiently mature to appropriately respond to cisplatin, presumably as a result of the presence of basolateral organic cation transporter 2 (OCT2) and copper transporter 1, which mediate uptake of cisplatin into these tubular cells 39, 40 . Hence, kidney organoids should be of value for the screening of pharmaceuticals.
Modeling genetic renal disease using kidney organoids is another useful application. Kidney organoids using iPSCs that are generated from readily accessible somatic cells (e.g., skin fibroblasts or leukocytes) from patients with inherited kidney disease may recapitulate features of these renal disorders in vitro 37 . Such disorders include autosomal dominant/recessive polycystic kidney disease, medullary cystic kidney disease, nephronophthisis, Alport syndrome and Bartter syndrome 41 . However, considering the likely variability in forming kidney organoids among iPSC lines, it will be desirable to compare mutant iPSCs with a proper isogenic control iPSC line. This can be done using genome-editing tools such as the clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 system to artificially generate a specific genetic mutation in an iPSC line 37 . It may be yet more advantageous to correct the mutation in patient-derived iPSCs, again using CRISPR/Cas9 technology, in order to generate an isogenic control iPSC line. This will be possible only in instances in which the underlying mutation has been identified.
Despite substantial possibilities, the protocol has limitations and is likely to benefit from further protocol improvements. Kidney organoids at day 18 in 3D culture, while transcriptionally similar to those found in the first-trimester human kidney 16 , have not matured to the level of the adult kidney. Consistent with a previous study of cadherin expression in the developing mouse kidney 42, 43 , we showed that more mature proximal tubules in kidney organoids expressed ECAD 16 . Cultured human proximal tubule cells also express ECAD 44 ; however, some reports suggest that terminally differentiated proximal tubules in adult human kidney reveal no or very low ECAD expression 45 . This protocol has not generated kidney organoids that reach an adult stage of maturation. This is evident by a lack of expression of some mature renal tubule markers; also, capillary loops do not form in most glomeruli. Hence, it is highly likely that organoid-culture conditions may require further optimization to reach maturation. This immaturity may be problematic when studying disease modeling, because most aforementioned inherited kidney diseases develop after birth, and some do not develop until adulthood. In addition, it is important to note that, from the anatomical and functional points of view, the kidney organoid is not a kidney in miniature form. The mature kidney filters the blood to form a urinary filtrate before reclaiming the majority of this fluid to finally produce 1-1.5 liters of urine a day. During this process, the kidney also removes nitrogenous and toxic wastes, regulates electrolytes, maintains acid-base balance and regulates blood pressure, via selective tubular reabsorbtion, secretion and hormone production. To recapitulate such diverse functions would require hPSC-derived kidney organoids not only to be reasonably large and composed of mature cell types but also to develop a vascular access and a single exit path for urine, both of which are currently missing in current kidney organoids.
Experimental design hPSC culture for differentiation. This protocol can be applied to both hESCs and hiPSCs. We have successfully applied the method described here to both hESCs (HES-3, commercially available) and hiPSCs (CRL1502 clone C32) that were authenticated and tested for mycoplasma infection 46 . Cells were maintained on a mouse embryonic fibroblast (MEF) feeder layer and passaged using TrypLE Select. However, before the differentiation began, the cells were adapted to feeder-free conditions with MEF-conditioned medium and Matrigel-coated culture dishes. This is to eliminate MEFs from the differentiation culture to avoid any unknown influence of MEFs on the differentiation. The differentiation begins with hPSC density at ~40-50% confluency (Step 24), which can be obtained by plating ~15,000 cells per cm 2 the day before (Step 23). This plating cell number depends on the cell cycle speed and recovery rate; hence, it should be adjusted for each hPSC line/clone. 34, 47, 48 . In an embryo, AP patterning in the intermediate mesoderm is associated with primitive streak cell migration, in which cells migrate from the caudal to the rostral direction, during which they are exposed to canonical WNTs, followed by FGF9 and retinoic acid (RA) 38 . Hence, earlier-migrating cells, which are exposed to WNTs for a shorter period of time, give rise to the anterior intermediate mesoderm, whereas cells migrating later are exposed to WNTs for a longer period of time and form the posterior intermediate mesoderm. In the protocol, hPSCs are treated with the glycogen synthase kinase (GSK-3) inhibitor, CHIR99021, to induce canonical WNT signaling (Fig. 1) . This differentiates hPSCs into the posterior primitive streak that expresses T and MIXL1 with minimum expression of SOX17, which is a marker of the anterior primitive streak 9 . CHIR99021 is added to hPSC culture for 3-4 d, which is an intermediate duration designed to induce both the anterior and the posterior intermediate mesoderm at the same time ( Fig. 1) . In this protocol, we use CHIR99021. Conversely, a shorter (<3 d) or longer (>4 d) phase of CHIR99021 administration results in the predominant induction of the anterior or posterior intermediate mesoderm, respectively. The medium period of CHIR99021 administration may vary depending on hPSC clones and lines to use; therefore, it needs to be optimized to avoid obtaining a onesided intermediate mesoderm population of either GATA3 + or HOXD11 + cells at day 7 of the differentiation 16 . As generally seen in human hPSC differentiation, each hPSC line or clone has its own propensity to develop toward a certain cell fate more (or less) easily than other lineages 49 , and we noticed during the initial step of the differentiation that distinct clones respond to CHIR99021 differently. To generate kidney organoids reproducibly, it is recommended that the protocol be tested once with distinct hES/iPSC lines or distinct hiPSC clones, even when derived from the same individual, and that the researcher choose the most responsive lines or clones to use thereafter. Hence, an optimal CHIR99021 concentration and differentiation time period may be required for each line-e.g., a range of 2-5 d of CHIR99021 administration first, and then maintenance of concentrations between 6 and 10 µM CHIR99021, if necessary.
Kidney organoid formation. The kidney progenitor aggregate includes the ureteric epithelium and the metanephric mesenchyme; hence, their reciprocal interaction spontaneously initiates nephrogenesis. However, to maximize nephron formation, the protocol stimulates the organoids with a high concentration of CHIR99021 for 1 h. After the CHIR99021 pulse, the organoids should be supplemented with FGF9 to maximize the development of nephrons. We found that five additional days of FGF9 supplementation was sufficient to obtain maximal nephrogenesis. Subsequently, the organoids should be cultured in growth factorfree APEL medium 50 for further self-organization (Fig. 1) . The resulting organoids are regarded as successful based on the presence of appropriately segmented nephrons and surrounding stromal and endothelial cell populations ( Table 1) . as it solidifies when warmed to temperatures >16 °C. P200 pipette tips should also be prechilled before use. bFGF (10 mg/ml) Centrifuge the tube at 1,000-3,000g for 10 s at room temperature before opening. Reconstitute to 10 µg/ml in a filtered solution of 0.5% (wt/vol) BSA, 1 mM DTT and 10% (vol/vol) glycerol in DPBS. Prepare aliquots of appropriate amounts and store them at −80 °C for up to 6 months. bFGF can be stored at 4 °C for up to 2 weeks once it is thawed. FGF9 (100 mg/ml) Centrifuge the tube at 1,000-3,000g for 10 s at room temperature before opening. Reconstitute to 100 µg/ml in filtered DPBS containing 0.1% (wt/vol) human serum albumin. Prepare aliquots of appropriate amounts and store them at −80 °C for up to 6 months. FGF9 can be stored at 4 °C for up to 2 weeks once it is thawed. Heparin solution (1 mg/ml) Reconstitute to 1 mg/ml in ultrapure water and filter-sterilize it through a polyethersulfone (PES) 0.22-µm syringe-driven filter unit. Heparin solution can be stored at 4 °C for >12 months. CHIR99021 (10 mM) Centrifuge the tube at 1,000-3,000g for 10 s at room temperature before opening. Reconstitute 10 mg of CHIR99021 in 2.149 ml of DMSO to make a 10 mM stock. Prepare aliquots of appropriate amounts and store them at −20 °C for up to a year. 0.1% (wt/vol) Gelatin solution For 500 ml of 0.1% (wt/vol) gelatin solution, dissolve 0.5 g of gelatin in 500 ml of ultrapure water or DPBS, and autoclave it. The solution can be stored at 4 °C for up to 3 months. MEF culture medium For preparing 500 ml of MEF culture medium, combine 442.5 ml of DMEM high glucose, 50 ml of FBS, 5 ml of GlutaMAX-1 and 2.5 ml of penicillin/streptomycin. Filter-sterilize the medium through a PES 0.22-µm vacuum-driven filter unit and store it at 4 °C for up to 2 weeks.
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• hESC medium For preparing 500 ml of hESC medium, combine 386.5 ml of DMEM/F-12, 100 ml of knockout serum replacement, 5 ml of GlutaMAX-1, 5 ml of non-essential amino acids, 2.5 ml of penicillin/streptomycin and 1 ml of 2-mercaptoethanol (55 mM). Filter-sterilize the medium through a PES 0.22-µm vacuum-driven filter unit and store it at 4 °C for up to 2 weeks. To ensure that bFGF is fresh, supplement the medium with 10 ng/ml bFGF only just before use for hPSC maintenance. MEF-conditioned hESC medium Seed 1 × 10 7 mitotically inactivated MEFs into a 175-cm 2 tissue culture flask containing 40 ml of MEF culture medium. The next day, change the culture medium to 40 ml of hESC medium without bFGF. After overnight culture, collect the conditioned medium in a 500-ml bottle and store it at 4 °C. Feed MEFs again with 40 ml of fresh hESC medium. Repeat this cycle another 6 times to pool 280 ml of the conditioned medium in total. Filter-sterilize the medium through a PES 0.22-µm vacuum-driven filter unit and prepare aliquots in 50-ml tubes. Store the tubes at −20 °C for up to 6 months. MEF-conditioned hESC medium can be stored at 4 °C for up to 2 weeks once it is thawed. To ensure that bFGF is fresh, supplement the medium with 10 ng/ml bFGF only just before use for hPSC maintenance. APEL medium Once a bottle of APEL (100 ml volume) is opened, add 0.5-1 ml of antibiotic-antimycotic and store it at 4 °C for up to 2 weeks. Frozen stock of hPSCs For expanding hPSCs before cryopreserving them, cells are cultured in hESC medium supplemented with 10 ng/ml of bFGF on a mitotically inactivated MEF feeder layer by a single-cell culture method in which cells are passaged using TrypLE Select, as described in procedure Steps 1-9. Once the desired number of hPSCs is reached, harvest cells using TrypLE Select, then centrifuge (400g for 3 min at room temperature) and resuspend them in 10% DMSO/90% FBS. Split the cell suspension into cryo-vials at a volume of 1 ml per vial. Typically, hPSCs of 100% confluency in a 75-cm 2 tissue culture flask are split into nine cryo-vials, so that each cryo-vial contains 1.5-2.0 × 10 6 cells. Freeze the vials in a freezing container at −80 °C overnight, and subsequently store them in liquid nitrogen.  crItIcal We have experienced a huge variability in differentiation success rates between experiments when cells were obtained from a continuously maintained cell culture pool. To minimize this variation, hPSCs should be thawed one by one from a cryopreserved stock for each experiment. 2% (wt/vol) PFA (100 ml) Add 2 g of PFA and 10 µl of 10 N NaOH to 80 ml of DPBS at 60 °C, and mix the solution until the powder dissolves. Adjust the final volume up to 100 ml by adding DPBS. Prepare aliquots of appropriate amounts and store them at −20 °C for up to 1 month. ! cautIon PFA is toxic, and it must be handled inside a fume hood with masks and goggles. Blocking buffer (50 ml) Dissolve 5 ml of donkey serum and 30 µl of TritonX in 45 ml of DPBS. Prepare aliquots of appropriate amounts. Blocking buffer can be stored at −20 °C for up to 1 year. 2| Prepare 10 ml of prewarmed MEF culture medium in a 15-ml conical tube.
3| Thaw a frozen vial of mitotically inactivated MEFs in a 37 °C water bath until a small ice pellet remains. Transfer MEFs to a 15-ml conical tube containing prewarmed MEF culture medium in a dropwise manner, and centrifuge at 400g for 3 min at room temperature.
4|
Remove the supernatant and resuspend the MEFs in MEF culture medium. Count the cell number using a hemocytometer. Make a cell suspension of 3 × 10 5 cells in 5 ml of MEF culture medium. Remove the gelatin and seed the cells onto a gelatin-coated 25-cm 2 tissue culture flask to obtain a density of 12 × 10 3 cells per cm 2 and incubate the flask overnight in a 37 °C CO 2 incubator.
hpsc thawing • tIMInG 30 min 5| Prepare 10 ml of prewarmed hESC medium in a 15-ml conical tube.
6| Thaw a frozen vial of hPSCs containing 1.5-2.0 × 10 6 cells in a 37 °C water bath until a small ice pellet remains. Transfer hPSCs to a 15-ml conical tube containing prewarmed DMEM/F-12 in a dropwise manner and centrifuge the tube at 400g for 3 min at room temperature.
7|
Remove the supernatant and resuspend the cells in 5 ml of hESC medium supplemented with 10 ng/ml bFGF.
8|
Remove the MEF culture medium from the flask containing mitotically inactivated MEFs, and plate the above hPSC suspension. Incubate the MEFs overnight in a 37 °C CO 2 incubator. 
Growing hpscs on the
11|
To passage hPSCs onto the Matrigel, wash the hPSCs on the MEF feeder layer in a 25-cm 2 tissue culture flask with 3 ml of DPBS twice. Aspirate the DPBS.
12| Add 1 ml of TrypLE Select to the cells and incubate the flask at 37 °C for 3 min.
13| Pipette 11 ml of DMEM/F-12 onto the cells, mix well and ensure that the cells have lifted off of the plastic surface.  crItIcal step Pipette the cells no more than twice, as hPSCs are very sensitive.
14| Collect 4 ml of cell suspension in a 15-ml tube to obtain a 1:3 split ratio, and centrifuge the tube at 400g for 3 min at room temperature. Alternatively, a 1:2 split ratio can be chosen to achieve 70-100% confluency at Step 17.
15|
Remove the supernatant and add 5 ml of MEF-conditioned hESC medium supplemented with 10 ng/ml bFGF to the cells.
Mix it gently.
16| Aspirate Matrigel-containing DMEM/F-12 from a prepared Matrigel-coated 25-cm 2 tissue culture flask, and seed the cells from Step 15. Culture them in a 37 °C CO 2 incubator for 2 d, with daily changing of MEF-conditioned hESC medium supplemented with 10 ng/ml bFGF. 20| Collect the cell suspension in a 15-ml tube. Count the cell number using a hemocytometer.
21|
Calculate the cell suspension volume to achieve 375,000 cells.
22|
Divide the cells into aliquots in 15-ml tubes. Centrifuge the tube at 400g for 3 min at room temperature.
23|
Remove the supernatant and resuspend the cells in 4 ml of MEF-conditioned hESC medium supplemented with 10 ng/ml bFGF. Seed the cells onto a prepared Matrigel-coated 25-cm 2 tissue culture flask to obtain a density of 15 × 10 3 cells per cm 2 .
Culture them overnight in a 37 °C CO 2 incubator.
Inducing the intermediate mesoderm • tIMInG 7 d 24|
Aspirate the MEF-conditioned hESC medium from the 25-cm 2 tissue culture flask.  crItIcal step Cells should reach 40-50% confluency on this day. If not, adjust the cell number for plating at
Step 21 (Fig. 2b) .
25| Add 4 ml of APEL medium containing 8 µM CHIR99021 to hPSCs. 
26|
28|
Culture the cells in a 37 °C CO 2 incubator, refreshing the medium every 2 d until day 7 of differentiation, counting
Step 24 as day 0; this includes both CHIR99021 phase and FGF9 phase.
Forming aggregates for developing kidney organoids • tIMInG 11-18 d 29| Aspirate the culture medium and wash the cells with 3 ml of DPBS. Aspirate the DPBS.
30| Add 1 ml of trypsin EDTA (0.05%) to the cells and incubate them at 37 °C for 3 min.
31|
Monitor with the microscope to make sure that all cells have lifted off of the surface after 2 min. If the cells are still attached to the surface, gently pipette the cells with trypsin and place them back into the incubator for a further 1 min.
32|
Transfer the cell suspension to a 15-ml tube containing 9 ml of MEF culture medium to neutralize the trypsin. Centrifuge the tube at 400g for 3 min at room temperature.
33|
Aspirate the supernatant and resuspend the cells with 3 ml of APEL medium.
34|
Remove 10 µl of cell suspension and perform a cell count with a hemocytometer.
35| Each organoid will have roughly 5 × 10 5 cells. Add the required amount of cell suspension to a 1.5-ml microcentrifuge tube. Centrifuge the tube at 400g for 2 min at room temperature to make a cell pellet.
36| Add 1.2 ml of APEL containing 5 µM CHIR99021 to a six-well Transwell cell culture plate. The Transwell filter attaches to the surface of the medium.
37|
Pick up pellets by using a P1,000 or P200 wide-bore tip.
? troublesHootInG 38| Carefully place the pellets onto the six-well Transwell filter with minimal APEL medium carryover. Incubate the pellets at 37 °C for 1 h.
39| After 1 h of incubation, remove the APEL medium containing 5 µM CHIR99021, and add 1.2 ml of APEL medium supplemented with 200 ng/ml FGF9 and 1 µg/ml heparin. 
40|
44|
Remove the PFA and wash the organoids three times with DPBS.  pause poInt Once they are fixed and washed, organoids can be stored at 4 °C for several months before immunofluorescence staining.
45| Transfer ~150 µl of blocking buffer to the MatTek glass-bottom dishes.
46|
Carefully cut the organoids off the filter and submerge the filter in the blocking buffer.
47|
Block the organoids at room temperature for 2-3 h, and gently shake the dish using a rocker during incubation.
48|
Prepare primary antibodies of choice in blocking buffer with appropriate dilutions (table 1).
49|
Aspirate the blocking buffer from the MatTek dish, and add 150 µl of blocking buffer containing primary antibodies to the MatTek dish.
50|
Incubate the organoids with primary antibody solution at 4 °C overnight.  crItIcal step Make sure that the organoids are completely submerged in the solution. Preferably, gently shake the dish using a rocker during incubation.
51|
Aspirate the primary antibody solution from the dish and wash the organoids with PBTX (0.3% (vol/vol) TritonX/DPBS) six times, for 10 min each with gentle shaking.
52| Prepare secondary antibodies (1:400 dilution) of choice in PBTX.
53|
Aspirate PBTX from the MatTek dish, and add 150 µl of PBTX containing secondary antibodies to the MatTek dish.
54|
Incubate the organoids in the secondary antibody solution at 4 °C overnight.
55|
Remove the secondary antibody solution and incubate with DAPI (1:1,000 dilution) in DPBS for 3 h.
56|
Wash the organoids with DPBS for 10 min, three times.
57|
Image the organoids using a laser confocal microscope.
? troublesHootInG Troubleshooting advice can be found in table 2.
• antIcIpateD results This protocol produces kidney organoids from hPSCs with a high success rate. Success is defined as the presence of organoids containing segmented nephrons composed of collecting duct, renal interstitium and endothelium. We have successfully generated organoids from both human ESC lines (HES-3) and human iPSC lines (CRL1502 clone C32, as well as and a number of patient-derived iPSC lines derived in-house (data not shown)). In addition, there is little variation between organoids within an experiment 16 . When the differentiation starts with CHIR99021 administration ( Fig. 1; day 0 ), hPSCs on Matrigel should retain pluripotency, as indicated by the expression of stem cell markers such as OCT4 and NANOG, and show the anticipated morphology of a large nucleus, although defined borders of colonies are typically not seen at this stage (Fig. 2a,b) . After 2 d of CHIR99021 exposure, colonies break apart into single cells with a spiky, typically triangular, morphology (Fig. 2c) . This is evidence of the EMT expected of hPSCs differentiating into the primitive streak. Once the 3-4 d of the CHIR99021 phase end (Fig. 2d) and the culture medium contains FGF9, the cells start growing rapidly to reach confluence by day 7 of differentiation. The surface of the cell layer at day 7 typically looks 'hilly' because of the contrast between thin and thick cell layers (Fig. 2e) . Occasionally, cells form balls by day 7, which indicates that the initial duration of administration of CHIR99021 or the CHIR99021 concentration should be slightly shortened or reduced, respectively, for an optimal result. If immunofluorescence on this day shows a predominant population of either GATA3 + or HOXD11 + cells, adjust the number of days of CHIR99021 administration to obtain both populations (Fig. 3a) 16 . The size of pellets composed of 5 x 10 5 cells is ~2 mm in diameter (Fig. 2f) . This pellet initiates nephrogenesis by developing renal vesicles in 3 d under the 3D culture (organoid culture) conditions. The presence of renal vesicles can be confirmed under a tissue culture microscope (Fig. 2g,h ). In the case of a failure of nephrogenesis, organoids look like a pancake and lack any complex structures. After 11 d of organoid culture, if the differentiation has worked properly, obvious formation of glomeruli, as well as tubular structures, can be observed (Fig. 2i,j) . The resulting kidney organoid will grow up to 6 mm in diameter by 18 d of organoid culture ( Fig. 1 day 25 ). To evaluate tissues in kidney organoids, whole-mount immunofluorescence can be performed (Steps 44-58) . Within the organoid, a number of different kidney cell types are visible (table 1), including collecting ducts marked by PAX2, GATA3 and ECAD staining (Fig. 3b) , loops of Henle marked by UMOD staining (Fig. 3c) , proximal tubules marked by LTL and cubilin (CUBN) staining (Fig. 3d) , the podocyte of the glomerulus marked by WT1 and NPHS1 staining (Fig. 3f) and basement membrane in glomeruli marked by LAM staining (Fig. 3g arrowheads) , early mesangial cells marked by PDGFRA staining (Fig. 3h) , distal tubules marked by ECAD staining in the absence of costaining with either LTL or GATA3 (Fig. 3f) , medullary interstitium marked by MEIS1 alone and cortical interstitium marked by MEIS1 and FOXD1 staining 51 (Fig. 3e) , as well as an endothelial network marked by CD31 (PECAM), KDR and SOX17 staining (Fig. 3h,i) . Endothelial networks tend to run in between nephrons and also on the surface of the organoid (Fig. 3j) . Four-color staining using NPHS1, LTL, ECAD and GATA3 antibodies/lectin enables the identification of segmented nephrons in the kidney organoid (Fig. 3k) . Typically, larger-sized kidney organoids develop nephrons densely in the peripheral region and have a renal interstitium and an endothelial network growing in the center (Fig. 3l) .
